^
CANCER:

Germ Cell Tumors

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
No biomarker
Germ Cell Tumors
dactinomycin
Sensitive
:
A1
No biomarker
Germ Cell Tumors
ifosfamide
Sensitive
:
A1
No biomarker
Germ Cell Tumors
TI-CE
Sensitive
:
A2
No biomarker
Germ Cell Tumors
CaT
Sensitive
:
A2
No biomarker
Germ Cell Tumors
VC
Sensitive
:
A2
No biomarker
Germ Cell Tumors
GemOx
Sensitive
:
A2
No biomarker
Germ Cell Tumors
BEP
Sensitive
:
A2
No biomarker
Germ Cell Tumors
EP
Sensitive
:
A2
No biomarker
Germ Cell Tumors
VIP
Sensitive
:
A2
No biomarker
Germ Cell Tumors
VAC
Sensitive
:
A2
No biomarker
Germ Cell Tumors
VeIP
Sensitive
:
A2
No biomarker
Germ Cell Tumors
TIP
Sensitive
:
A2
TMB-H
Germ Cell Tumors
pembrolizumab
Sensitive
:
A2
No biomarker
Germ Cell Tumors
paclitaxel + ifosfamide
Sensitive
:
A2
No biomarker
Germ Cell Tumors
paclitaxel + gemcitabine
Sensitive
:
A2
No biomarker
Germ Cell Tumors
paclitaxel
Sensitive
:
A2
No biomarker
Germ Cell Tumors
carboplatin + docetaxel
Sensitive
:
A2
No biomarker
Germ Cell Tumors
docetaxel
Sensitive
:
A2
No biomarker
Germ Cell Tumors
etoposide IV
Sensitive
:
A2
No biomarker
Germ Cell Tumors
paclitaxel + gemcitabine + oxaliplatin
Sensitive
:
A2
MSI-H/dMMR
Germ Cell Tumors
pembrolizumab
Sensitive
:
A2
BRCA1 mutation
Germ Cell Tumors
olaparib
Sensitive
:
C1
XPA expression
Germ Cell Tumors
cisplatin
Resistant
:
C3
MTOR mutation
Germ Cell Tumors
everolimus
Sensitive
:
C3
KRAS amplification
Germ Cell Tumors
MEK inhibitor
Sensitive
:
C3
Chr t(22)
Germ Cell Tumors
cisplatin + ifosfamide + etoposide oral + mesna
Sensitive
:
C4
EGFR L858R
Germ Cell Tumors
icotinib
Sensitive
:
C4
BAX underexpression
Germ Cell Tumors
cisplatin
Resistant
:
C4
TP53 mutation
Germ Cell Tumors
cisplatin
Resistant
:
C4
EGFR L858R
Germ Cell Tumors
icotinib
Sensitive
:
C4
MSH6 mutation
Germ Cell Tumors
camrelizumab
Sensitive
:
C4
BRCA2 mutation
Germ Cell Tumors
camrelizumab
Sensitive
:
C4